Drug · Other
Interferon Alfa-2b
CI-DRUG-00000678Explore in graph →CHEMBL1201558 Approved
Regulatory
Approvals (16)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as REBETRON SOLUTION (ALBUMIN (HUMAN) FREE) (18 MIU MULTI-DOSE PEN / 200MG CAPSULES) (DIN 02241159) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Oct 27, 2004 | Dec 23, 1999 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as INTRON A (DIN 02240694) under ATC L03AB05 INTERFERON ALFA-2B. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Feb 20, 2019 | Sep 23, 1999 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as INTRON A (DIN 02240693) under ATC L03AB05 INTERFERON ALFA-2B. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawn |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 14 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Withdrawn | Phase 4 | 1 | 0 | 5 | 23 | 16 | CA, EU | — | Aug 5, 1998 |
| Non-Hodgkin Lymphoma | Phase4 | Phase 4 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 1, 2014 |
| Leukemia | Phase3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | Oct 22, 1998 |
| Kaposi Sarcoma | Phase2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (24)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02737046 | Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma | completed | Phase 2 | 15 | University of MiamiOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT00003641 | High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma | active not recruiting | Phase 3 | 1,150 |